Anti-Obesity Agents

With its impact on individuals and society, addressing obesity requires a multidisciplinary approach that combines medical expertise, research and public health initiatives.

In this edition, AGA speaks out on controversial NordICC data; first US patient enrolled in phase 3 trial of obefazimod; ‘unprecedented’ shift in hepatitis A outbreaks and more.

The prevalence of overweight and obesity continues to rise in the United States and globally at an alarming rate. By 2025, data from the NCD Risk Factor Collaboration suggest 18% of men and 21% of women globally will have obesity.

Adults with obesity participating in a real-world, employer-based weight-management program were significantly more likely to achieve clinically meaningful weight loss when adding pharmacotherapy to shared monthly visits, data show.